Therapies modulating IL-6 (olokizumab or clazakizumab) or the α subunit of its receptor (tocilizumab or sarilumab) have been used clinically to treat inflammatory diseases, such as RA, systemic lupus erythematous (SLE), diabetes and, more recently, coronavirus disease 2019 (COVID-19) (184, 185) that may develop kidney disease, but no clinical trial studied kidney function or renal injury as primary outcome. The gene discussed is IL6; the disease is kidney disorder.